Regulatory Approvals and Advancements by Poolbeg, Arecor, hVIVO, Ilika, and Kodal Minerals
Poolbeg Pharma has secured MHRA approval for its trial, while Arecor Therapeutics progresses its insulin candidate. Key developments across multiple companies signal growth potential in their respective sectors.
Theia Market Signal Identification - AI Assisted
Poolbeg Pharma has obtained full MHRA approval for its TOPICAL trial at six UK locations, with interim data expected this summer. Arecor Therapeutics is advancing its insulin candidate AT278, with a Phase 2 trial planned for late 2026, supported by a partnership with Sequel Med Tech. hVIVO reported an EBITDA exceeding guidance and ended 2025 with over £14 million in cash, forecasting high single-digit revenue growth for 2026.
Ilika is set to test its Goliath solid-state battery in Brompton's e-bike in 2027, potentially impacting markets like China. Kodal Minerals recorded over 10,900 tonnes of lithium concentrate shipped from the Bougouni project, with total revenues surpassing $51 million since exports commenced. The developments indicate a positive trend for investment and technological innovation in the biotech and minerals sectors.
Comments